While LITT has been shown to be an effective, well-tolerated alternative to open surgical resection in both low- [4,24,25] and high-grade [14,26,27] gliomas, LITT treatment outcomes specific to IDH1/2 mutant grade 2 and 3 gliomas have not been studied. This evidence concerns the gene IDH1 and glioma.